Baseline characteristics of the study patients
Characteristic . | All patients (N = 159) . | mPRS group . | P . | ||
|---|---|---|---|---|---|
| Higher benefit (n = 74) . | Intermediate benefit (n = 31) . | Lower benefit (n = 54) . | |||
| Age, median (range), y | 75 (61-89) | 74 (61-89) | 75 (62-86) | 75 (61-86) | .934 |
| Male sex, n (%) | 92 (57.9) | 45 (61) | 20 (65) | 27 (50) | .334 |
| Ethnicity, n (%) | .002 | ||||
| White | 126 (79.2) | 68 (91.9) | 24 (77.4) | 34 (63) | |
| Black | 7 (4.4) | 1 (1.4) | 1 (3.2) | 5 (9.3) | |
| Hispanic | 11 (7) | 3 (4.1) | 2 (6.5) | 6 (11.1) | |
| Asian | 6 (3.8) | 2 (2.7) | 0 | 4 (7.4) | |
| Median hemoglobin level, g/L (range) | 9.0 (7.1-12.7) | 9.2 (7.2-12.7) | 8.9 (7.1-10.9) | 8.9 (7.1-10.9) | .042 |
| Median WBC count, ×109 cells per L (range) | 2.9 (0.3-81.1) | 2.6 (0.6-81.1) | 3.9 (0.7-43.1) | 3.05 (0.30-72.60) | .875 |
| Median platelet count, ×109 cells per L (range) | 41 (4-368) | 54 (4-310) | 35 (5-368) | 36 (5-174) | .035 |
| Median bone marrow blast percentage (range) | 39 (11-95) | 39 (16-95) | 47 (22-86) | 36 (11-88) | .151 |
| Cytogenetics, n (%) | |||||
| Normal karyotype | 56 (35.2) | 37 (50) | 17 (54.8) | 2 (3.7) | <.001 |
| Chromosome 5/5q abnormality | 48 (30.2) | 9 (12.2) | 0 | 39 (72.2) | <.001 |
| Chromosome 7 abnormality | 29 (18.2) | 4 (5.4) | 2 (6.5) | 23 (42.6) | <.001 |
| Chromosome 17 abnormality | 26 (16.4) | 3 (4.1) | 2 (6.5) | 21 (38.9) | <.001 |
| t(6;9) | 1 (0.6) | 0 | 1 (3.2) | 0 | .129 |
| MECOMr | 5 (3.1) | 2 (2.7) | 2 (6.5) | 1 (1.9) | .491 |
| KMT2Ar | 3 (1.9) | 3 (4.1) | 0 | 0 | .164 |
| Complex karyotype | 63 (39.6) | 10 (13.5) | 5 (16.1) | 48 (89) | <.001 |
| Mutation, n (%) | |||||
| TP53 | 54 (34) | 0 | 0 | 54 (100) | <.001 |
| NPM1 | 33 (20.6) | 22 (29.7) | 10 (32.3) | 1 (1.9) | <.001 |
| TET2 | 29 (18.2) | 17 (23) | 6 (19.4) | 6 (11.1) | .227 |
| ASXL1 | 28 (17.6) | 13 (17.6) | 11 (35.5) | 4 (7.4) | .006 |
| DNMT3A | 28 (17.6) | 11 (14.9) | 8 (25.8) | 9 (16.7) | .381 |
| SRSF2 | 28 (17.6) | 18 (24.3) | 5 (16.1) | 5 (9.3) | .054 |
| NRAS/KRAS | 31 (19.5) | 0 | 26 (83.9) | 5 (9.3) | <.001 |
| RUNX1 | 23 (14.5) | 15 (20.3) | 5 (16.1) | 3 (5.6) | .048 |
| IDH1/2 | 34 (21.4) | 22 (29.7) | 9 (29) | 3 (5.6) | .001 |
| FLT3-ITD | 7 (3.9) | 0 | 7 (22.6) | 0 | <.001 |
| Therapy-related AML, n (%) | 33 (20.8) | 13 (17.6) | 3 (9.7) | 17 (31.5) | .038 |
| Secondary AML, n (%) | 29 (18.2) | 15 (20.3) | 6 (19.4) | 8 (14.8) | .721 |
| Treatment protocol, n (%) | .130 | ||||
| Aza7Ven | 16 (10.1) | 9 (12.2) | 5 (16.1) | 2 (3.7) | |
| Dec10Ven | 86 (54.1) | 40 (54.1) | 12 (38.7) | 34 (63) | |
| Dec5Ven | 57 (35.8) | 25 (33.8) | 14 (45.2) | 18 (33.3) | |
Characteristic . | All patients (N = 159) . | mPRS group . | P . | ||
|---|---|---|---|---|---|
| Higher benefit (n = 74) . | Intermediate benefit (n = 31) . | Lower benefit (n = 54) . | |||
| Age, median (range), y | 75 (61-89) | 74 (61-89) | 75 (62-86) | 75 (61-86) | .934 |
| Male sex, n (%) | 92 (57.9) | 45 (61) | 20 (65) | 27 (50) | .334 |
| Ethnicity, n (%) | .002 | ||||
| White | 126 (79.2) | 68 (91.9) | 24 (77.4) | 34 (63) | |
| Black | 7 (4.4) | 1 (1.4) | 1 (3.2) | 5 (9.3) | |
| Hispanic | 11 (7) | 3 (4.1) | 2 (6.5) | 6 (11.1) | |
| Asian | 6 (3.8) | 2 (2.7) | 0 | 4 (7.4) | |
| Median hemoglobin level, g/L (range) | 9.0 (7.1-12.7) | 9.2 (7.2-12.7) | 8.9 (7.1-10.9) | 8.9 (7.1-10.9) | .042 |
| Median WBC count, ×109 cells per L (range) | 2.9 (0.3-81.1) | 2.6 (0.6-81.1) | 3.9 (0.7-43.1) | 3.05 (0.30-72.60) | .875 |
| Median platelet count, ×109 cells per L (range) | 41 (4-368) | 54 (4-310) | 35 (5-368) | 36 (5-174) | .035 |
| Median bone marrow blast percentage (range) | 39 (11-95) | 39 (16-95) | 47 (22-86) | 36 (11-88) | .151 |
| Cytogenetics, n (%) | |||||
| Normal karyotype | 56 (35.2) | 37 (50) | 17 (54.8) | 2 (3.7) | <.001 |
| Chromosome 5/5q abnormality | 48 (30.2) | 9 (12.2) | 0 | 39 (72.2) | <.001 |
| Chromosome 7 abnormality | 29 (18.2) | 4 (5.4) | 2 (6.5) | 23 (42.6) | <.001 |
| Chromosome 17 abnormality | 26 (16.4) | 3 (4.1) | 2 (6.5) | 21 (38.9) | <.001 |
| t(6;9) | 1 (0.6) | 0 | 1 (3.2) | 0 | .129 |
| MECOMr | 5 (3.1) | 2 (2.7) | 2 (6.5) | 1 (1.9) | .491 |
| KMT2Ar | 3 (1.9) | 3 (4.1) | 0 | 0 | .164 |
| Complex karyotype | 63 (39.6) | 10 (13.5) | 5 (16.1) | 48 (89) | <.001 |
| Mutation, n (%) | |||||
| TP53 | 54 (34) | 0 | 0 | 54 (100) | <.001 |
| NPM1 | 33 (20.6) | 22 (29.7) | 10 (32.3) | 1 (1.9) | <.001 |
| TET2 | 29 (18.2) | 17 (23) | 6 (19.4) | 6 (11.1) | .227 |
| ASXL1 | 28 (17.6) | 13 (17.6) | 11 (35.5) | 4 (7.4) | .006 |
| DNMT3A | 28 (17.6) | 11 (14.9) | 8 (25.8) | 9 (16.7) | .381 |
| SRSF2 | 28 (17.6) | 18 (24.3) | 5 (16.1) | 5 (9.3) | .054 |
| NRAS/KRAS | 31 (19.5) | 0 | 26 (83.9) | 5 (9.3) | <.001 |
| RUNX1 | 23 (14.5) | 15 (20.3) | 5 (16.1) | 3 (5.6) | .048 |
| IDH1/2 | 34 (21.4) | 22 (29.7) | 9 (29) | 3 (5.6) | .001 |
| FLT3-ITD | 7 (3.9) | 0 | 7 (22.6) | 0 | <.001 |
| Therapy-related AML, n (%) | 33 (20.8) | 13 (17.6) | 3 (9.7) | 17 (31.5) | .038 |
| Secondary AML, n (%) | 29 (18.2) | 15 (20.3) | 6 (19.4) | 8 (14.8) | .721 |
| Treatment protocol, n (%) | .130 | ||||
| Aza7Ven | 16 (10.1) | 9 (12.2) | 5 (16.1) | 2 (3.7) | |
| Dec10Ven | 86 (54.1) | 40 (54.1) | 12 (38.7) | 34 (63) | |
| Dec5Ven | 57 (35.8) | 25 (33.8) | 14 (45.2) | 18 (33.3) | |
KMT2Ar, KMT2A gene rearrangement; MECOMr, MECOM gene rearrangement; WBC, white blood cell.